Cancer in pregnancy overlooked, even with common symptoms

5 minute read


Women are fighting for diagnosis, and privilege is often ‘a prerequisite for survival’.


Pregnancy in cancer is rare but not insignificant, equivalent to a plane-load of women every year, but there’s very little data collected and diagnosis can be hard to come by, delegates at the 53rd COSA ASM heard earlier this month.

“It really is a privilege to be part of this panel, and my privilege is, in fact, why I’m here today. I am alive and I’m well, despite my stage IV BRAF mutated pregnancy-associated colorectal cancer diagnosis,” Sophie Boffa, who leads the Clinical Governance Unit at Safer Care Victoria and is on the Bowel Cancer Outcomes Registry (BCOR) Board, told those gathered for the morning session on early onset colorectal cancer.

“My wellness is heavily due to my health literacy, working in in the system and understanding how to navigate it, [and] having incredible support around me. But most crucially, it’s because my parents are doctors, and they were able to call in a life-saving second opinion from a very trusted colleague who has gone above and beyond for me and the family.

“Privilege should not be a prerequisite for survival, and yet for a particularly vulnerable patient cohort, it very often is.”

Pregnant women were often excluded from research, clinical registries, and clinical care guidelines. This invisibility compounded the disproportionate burdens borne by women with cancer, Ms Boffa said.

“Add pregnancy on top of this, and it really is a rather bleak situation.”

Although evidence around pregnancy-associated cancer (PAC), where a diagnosis was received during pregnancy or within 12 months of delivery, was limited, Australian data had shown an increasing incidence.

The most current information was from the July 2026 Victorian Northern Metro Integrated Transfer Service report, which said around 165 women a year were diagnosed with PAC, most commonly breast cancer (32.4%), thyroid and other endocrine cancers (14.2%), and haematological malignancies (11.7%).

But this number was probably an under-representation, because of reliance on incomplete data sets. The report relied on administrative hospital data from the Victorian Admitted Episodes Data Set, which had very limited clinical data and didn’t provide a complete capture of outpatient data, Ms Boffa explained.

Data on staging and maternal mortality were not captured by one registry but required data linkage across a number of databases, “which I don’t need to tell this audience is very costly and time-consuming,” Ms Boffa said.

The number of people with PAC might seem small, “but would we accept this level of mortality mobility in aviation? Would we accept a plane carrying 165 women dropping out of the sky each year?” Ms Boffa asked.

“We would expect improvement, and I don’t think this harm is any different. As the old saying does go, what gets measured gets done. If we can’t accurately evidence the need, it’s going to remain really difficult for us to attract funding to increase awareness, uplift capability, improve research, and develop best practice models of care and clinical guidelines.”

It was very difficult to provide personalised oncological care when data and evidence were limited, she noted.

It was also very difficult to get a timely diagnosis when clinicians were not aware of PAC, with the available evidence showing a trend of missed or delayed diagnosis.

“It took me 18 months and eight different specialist appointments to get my diagnosis. I had what I now know were four of the five most common bowel cancer symptoms. I had extreme unexplained weight loss, unrelenting fatigue, altered bowel habits, and abdominal pain.

“And I don’t say this to be critical or polarising. I know that no doctor gets up in the morning hoping to miss cancer in a young person. It is gutting for everybody, but it is happening,” Ms Boffa said.

She has started building her own database of women in Australia with pregnancy associated colorectal cancer.

“We quickly reached 45 women who had all had to agitate and advocate extensively to receive their diagnosis. There was an overrepresentation in this group of very aggressive mutations like BRAF and K-RAS, and tragically, many of them are no longer with us.”

Multidisciplinary care, a “cornerstone of modern oncology”, was difficult in PAC, which involved surgery, oncology, obstetrics, maternal-fetal medicine, neonatology, nursing, fertility preservation, and allied health, among others. It was hard to make timely care decisions when families and patients were left to coordinated these areas.

Equitable and timely access to fertility preservation was variable, and it was particularly complex for CRC patients, said Ms Boffa. In addition, fragmented care across locations and services led to poorer outcomes, she said.

“If we had a defined model of care or a dedicated PAC service, then we may be able to reduce the disparity and better mitigate the adverse outcomes that we see arising due to our varying health services’ capability and capacity.

“Path patients require complex clinical management and individualised decision making, and that very often is happening in the absence of any kind of clear or aligned international clinical guidance, and that exacerbates unwarranted variation in patient experiences and outcomes. I’ve witnessed my phenomenal team do this for six years in the dark.”

PAC patients also bore a heavy financial toxicity, coinciding with maternity leave, reduced employment, and childcare responsibilities, on top of any treatment-related costs.

“I’ve been asked to convince many women over and over again to have adjunct chemotherapy, not because they’re scared and they don’t understand the benefit, but because they can’t see a way of navigating the responsibilities of child caring and financial strain,” Ms Boffa said.

The 53rd Annual Scientific Meeting of the Clinical Oncology Society of Australia was held in Sydney from 11-13 November 2026.

End of content

No more pages to load

Log In Register ×